Replies to post #168493 on Biotech Values

[mcbio]

You can't look top line safety number like that, need detailed data presentation to see if there's any trend especially for chronic condition like RA. As of 2.8 vs 1.4%, the difference is just one patient, one out of 70 vs two out of 70!

Fair enough. But, I will be interested in comparing detailed safety data from this Phase 2b for VX509 to GLPG0634 once that Phase 2b data becomes available 2H14. It will be interesting to see if the theorized safety advantage of a JAK1 specific inhibitor shows in that data. Also important to compare efficacy obviously.